Original ArticlesCharacterization of 5-HT1A receptor functional coupling in cells expressing the human 5-HT1A receptor as assessed with the cytosensor microphysiometer
Introduction
Of the 15 different cloned 5-HT receptor subtypes identified to date (reviewed in Saxena, 1995), the 5-HT1A receptor subtype has been studied most extensively. In the CNS, this receptor subtype is located both presynaptically where it functions as an inhibitory autoreceptor suppressing the firing of dorsal raphe 5-HT neurons and postsynaptically in 5-HT projection regions within the frontal cortex and hippocampus. The therapeutic potential of 5-HT1A receptor ligands has largely driven the interest in this receptor subtype, and in this regard 5-HT1A partial agonists such as buspirone (Goa and Ward, 1986) and ipsapirone (Glaser, 1988) are clinically effective anxiolytics. In addition to an established role in anxiety, 5-HT1A receptors have been implicated as a therapeutic target in a number of other psychiatric disorders including obsessive compulsive disorder and depression (Deakin, 1993). Recently, it has been proposed that the combined action of a 5-HT1A receptor antagonist with a selective 5-HT reuptake inhibitor may result in a faster-acting antidepressant that may be efficacious in treatment-resistant patients (reviewed in Artigas et al., 1996).
One of the major challenges in the development of 5-HT1A receptor selective ligands has been the identification of selective antagonists which lack intrinsic activity in models of presynaptic 5-HT1A receptor function. For example, the earliest described 5-HT1A receptor antagonists BMY7378 and NAN-190 have subsequently been shown to exhibit partial agonist activity at presynaptic 5-HT1A receptors. Specifically, BMY7378 and NAN-190 act as partial 5-HT1A receptor agonists to suppress firing of rat dorsal raphe neurons in vitro (Greuel and Glaser, 1992). In addition, BMY7378 (Sharp et al., 1990) and NAN-190 (Hjorth and Sharp, 1990) decrease hippocampal 5-HT release in vivo via an agonist action at presynaptic 5-HT1A autoreceptors. However, major advances in the development of 5-HT1A receptor antagonists have been made with the development of WAY100135 (Fletcher et al., 1993) and WAY100635 (Forster et al., 1995) as selective 5-HT1A receptor antagonists. WAY100635 appears to act truly as a selective 5-HT1A receptor antagonist devoid of intrinsic agonist activity, while in vivo microdialysis studies demonstrate that WAY100135 results in a concentration-dependent reduction in hippocampal 5-HT levels (Assie and Koek, 1996), a property consistent with 5-HT1A partial agonist activity at presynaptic autoreceptors.
While the evaluation of 5-HT1A receptor ligands using in vivo models of presynaptic 5-HT1A receptor function has proven to be extremely powerful, these techniques are not amenable to the rapid evaluation of novel 5-HT1A receptor ligands. Accordingly, a number of recombinant cell lines expressing the human 5-HT1A receptor have been described, with particular emphasis on their potential to evaluate the intrinsic activity of 5-HT1A receptor ligands Boddeke 1992, Newman-Tancredi 1992, Varrault et al 1992. In this study, we have extended the functional analysis of recombinant human 5-HT1A receptors to include an evaluation of the Cytosensor microphysiometer, and its potential to detect 5-HT1A receptor functional agonist and antagonist activity. The microphysiometer continuously monitors the extracellular pH surrounding cells in culture, and reports receptor activation by measuring increases in extracellular acidification rate which occur in response to agonist stimulation. Consequently, the microphysiometer provides a signalling pathway-independent readout of receptor activation. Our objectives were to examine the potential use of the microphysiometer for the characterization of 5-HT1A receptor ligands and, in particular, to examine its ability to detect intrinsic activity of 5-HT1A ligands compared with other established methodologies. To this end, the results from this analysis have been compared with those obtained from a parallel study of the inhibition of forskolin-stimulated cAMP accumulation in h5-HT1A · CHO cells, which represents a more conventional assay of 5-HT1A receptor function in vitro.
Section snippets
Cell line
The PCR cloning of the human 5-HT1A receptor subtype from a human genomic library has been described previously (Chanda et al., 1993). A stable Chinese hamster ovary cell line expressing the human 5-HT1A receptor subtype (h5-HT1A · CHO cells) was employed throughout this study. Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum, nonessential amino acids and penicillin/streptomycin. All 5-HT1A receptor
Radioligand binding studies
A characterization of the h5-HT1A · CHO cell line was performed to establish expression levels and a radioligand binding profile. Using [3H]8-OH-DPAT as the radioligand, high-affinity saturable binding was observed in h5-HT1A · CHO cells. Saturation analysis revealed a Bmax (maximum site density) of 1.06 pmol/mg protein and a Kd (equilibrium dissociation constant) of 3.56 nM. The binding affinities (Ki) of several 5-HT1A ligands are depicted in Table 1. The affinities of these compounds
Microphysiometer studies of 5-HT1A receptor function
This study describes the characterization of the functional activity of a series of 5-HT1A receptor ligands using the agonist-stimulated increase in extracellular acidification rate, measured with the microphysiometer, as a functional assay. Although still considered to be a relatively new technique, microphysiometry has successfully been applied in the functional analysis of a large number of G-protein coupled receptors (GPCRs) including those that couple to effectors via Gαi (as is the case
Acknowledgements
The authors thank Stanley Nawoschik and Rafal Ochalski for their expert technical assistance.
References (39)
- et al.
Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists
Trends Neurosci
(1996) - et al.
Effects of 5-HT1A antagonists on hippocampal 5-hydroxytryptamine levels(S)-WAY100135, but not WAY100635, has partial agonist properties
Eur J Pharmacol
(1996) - et al.
WAY100135a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors
Eur J Pharmacol
(1993) - et al.
A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY100635
Eur J Pharmacol
(1995) - et al.
The putative 5-HT1A receptor antagonists NAN-190 and BMY7378 are partial agonists in the rat dorsal raphe nucleus in vitro
Eur J Pharmacol
(1992) - et al.
Is pindolol a mixed agonist-antagonist at central serotonin receptors?
Eur J Pharmacol
(1986) - et al.
Mixed agonist/antagonist properties of NAN-190 at 5-HT1A receptorsbehavioural and in vivo brain microdialysis studies
Life Sci
(1990) - et al.
An intracellular study of the action of NAN-190 on neurons in the dorsal raphe nucleus of the rat
Brain Res
(1992) - et al.
Partial agonists, full agonists, antagonistsdilemmas of definition
Trends Pharmacol Sci
(1993) - et al.
Pharmacological characterization of recombinant human 5-hydroxytryptamine1A receptors using a novel antagonist radioligand, [3H]WAY-100635
Life Sci
(1997)
Further assessment of the antagonist properties of the novel and selective 5-HT1A receptor ligands (+)-WAY100135 and SDZ 216-525
Eur J Pharmacol
Activity of serotonin (5-HT) receptor agonists, partial agonists and antagonists at cloned human 5-HT1A receptors that are negatively coupled to adenylate cyclase in permanently transfected HeLa cells
Biochem Pharmacol
Serotonin receptorssubtypes, functional responses and therapeutic relevance
Pharmacol Ther
Isolated adrenal cortex cellsACTH agonists, partial agonists, antagonists; cyclic AMP and corticosterone production
Arch Biochem Biophys
Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist BMY7378
Eur J Pharmacol
BMY 7378, a buspirone analog with high affinity, selectivity and low intrinsic activity at the 5-HT1A receptor in rat and guinea pig hippocampal membranes
Eur J Pharmacol
Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralininhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects
J Pharmacol Exp Ther
Agonist/antagonist interactions with cloned human 5-HT1A receptorsvariations in intrinsic activity studied in transfected HeLa cells
Naunyn Schmied Arch Pharmacol
Identification of residues important for ligand binding to the human 5-hydroxytryptamine1A serotonin receptor
Mol Pharmacol
Cited by (37)
Functional characterization of 5-HT<inf>1A</inf> and 5-HT<inf>1B</inf> serotonin receptor signaling through G-protein-activated inwardly rectifying K<sup>+</sup> channels in a fluorescence-based membrane potential assay
2020, Biochemical PharmacologyCitation Excerpt :The equipotent agonism exhibited by 5-HT and RU 24969 at 5-HT1A and 5-HT1B receptors is in good agreement with previous findings for 5-HT at recombinant and native receptors [45–54] and for RU 24969 at native receptors [51–54]. The >100-fold higher agonist potency exhibited by the prototypic 5-HT1A-selective agonist 8-OH-DPAT at 5-HT1A than at 5-HT1B [48,52,54–57] and the high 5-HT1A potency and ~20-fold lower 5-HT1B potency displayed by the promiscuous monoaminergic receptor agonist lisuride [47,58,59] also concord with the literature. While the low nanomolar EC50 values displayed by the atypical antipsychotic nemonapride at the 5-HT1A-cell lines in the FMP assay also is in agreement with previously studies [48,60,61], its ~20-fold 5-HT1A-over-5-HT1B selectivity can not be corroborated due to the lack of previously published functional data for it at 5-HT1B.
Involvement of α<inf>1B</inf>-adrenoceptors in the anti-immobility effect of imipramine in the tail suspension test
2015, European Journal of PharmacologyCitation Excerpt :However, the duration of immobility of mice treated with the highest doses of RS-100329 (1.0 mg/kg, i.p.) or BMY-7378 (0.5 and 1.0 mg/kg, i.p.) was not different from that observed in mice treated with saline and this lack of effect may result from a loss of selectivity of these drugs. BMY-7378 is a buspirone analogue that also shows high affinity and low efficacy at 5-HT1A serotonin receptors (Dunlop et al., 1998). However, it was shown that buspirone (3 to 30 mg/kg, i.p.) has no effect in the duration of immobility of gerbil in the tail suspension test (Varty et al., 2003), indicating that the effect observed with the lowest dose of BMY-7378 in the present study is not related to its actions at 5-HT1A serotonin receptors.
Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors
2011, European Journal of PharmacologyCitation Excerpt :Fig. 2 shows the dose–response curves of known ligands of the serotonin 5-HT2A and 5-HT2C receptors (Gαq-coupled receptors) (Fig. 2A), the serotonin 5-HT1A receptor (Fig. 2B), the dopamine D2L receptor (Fig. 2C) (Gαi-coupled receptors) and the serotonin 5-HT7 receptor (Gαs-coupled receptors) (Fig. 2D). In Table 1, the results obtained with the present method were compared with the findings from previous studies, and the results show that the pEC50 values obtained using the known ligands in the present assay were comparable to those determined from previous assays, such as phosphoinositide (PI) hydrolysis, the cAMP assay and the cell-based ELISA measurements of MAPK activation (Braden et al., 2006; Dunlop et al., 1998; Jordan et al., 2007a, 2007b; Lovenberg et al., 1993; Muntasir et al., 2006; Shapiro et al., 2003; Urban et al., 2007)(Table 1). In the present assay, aripiprazole behaved as a dopamine D2L receptor partial agonist, as did S(-)-3-PPP (Fig. 2C), which indicated that the present assay was sufficient to search for dopamine D2 receptor partial agonists with relatively low intrinsic activity.
Novel benzofuran derivatives with dual 5-HT<inf>1A</inf> receptor and serotonin transporter affinity
2010, Bioorganic and Medicinal Chemistry LettersNovel pyridyl-fused 3-amino chroman derivatives with dual action at serotonin transporter and 5-HT<inf>1A</inf> receptor
2007, Bioorganic and Medicinal Chemistry Letters